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This case report describes a rare clinical condition: metastasis of synchronous multiple primary tumors — skin melanoma and 
breast cancer in one axillary lymph node, confirmed with the results of clinical, morphological and immunohistochemical study 
of surgical material from 40 year-old woman.
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According to the numerous clinical studies, multiple 
primary malignant tumors (MPMT) are described 
as an independent appearance and development 
of two and more neoplasms in one patient. For the first 
time the definition of MPMT was provided by Billroth 
in 1869 who presented the following criteria for MPMT 
diagnostics: the tumors should be of different primary 
localization and different histological structure, while 
each tumor should develop its metastases [1–3]. I.e., 
a principal requirement for MPMT diagnostics is the 
difference between histological structure of the tu-
mors. At present time differential diagnostics is based 
on the use of immunohistochemical methods and 
methods of molecular biology that allow to reveal 
the principal differences between morphofunctional 
characteristics of the tumors [4, 5].
By the time of tumors appearance, MPMT could 
be described as synchronous tumors (developing 
simultaneously or in 6 months after diagnosis of the 
first tumor) or metachronous tumors (detected after 
different periods or 6 months after verification of the 
first tumor). By clinical obsevations, metachronous 
tumors occur more frequently than synchronous. Also, 
there are such groups of tumors as synchronous-
metachronous and metachronous-synchronous. Time 
interval that serves as the criterion of synchronicity 
and metachronicity, is conditional as far as the rates 
of tumor growth vary and depend on their localiza-
tion, histological structure and reactivity of the pa-
tient’s organism [4]. A special attention in the studies 
of polyneoplasms has been focused on simultaneous 
involvement of functionally dependent (esophagus, 
stomach, intestines) and hormonally dependent or-
gans and systems (thyroid gland, mammary gland, 
uterus, ovaries, adrenal gland, prostate). Along with 
this, it has been established that multiple tumors are 
often localized in functionally or hormonally unrelated 
organs and systems, creating a group of non-systema-
tized tumors. For example, in women the secondary 
tumors of stomach, ovaries, intestines, skin, thyroid 
gland develop after breast cancer [5].
Along with accumulation of cl inical  data 
on MPMT there have been done some attempts 
to assess the real frequency of multiple cancers. 
Back in 1926 G.G. Nepryakhin has collected the data 
of world literature and classified 487 MPMT cases 
revealed during post-mortem examination of cancer 
patients [2]. Higher frequency of MPMT detection 
at present time could be explained by several fac-
tors: a) better tumor diagnostics with the use of new 
methods for patient’s examination (endoscopy, ultra-
sound diagnostics, computed tomography, magnetic 
resonance imaging, positron emission tomography; 
immunoenzyme assays, immunohistological, molecu-
lar-genetic methods for analysis of surgical material); 
b) the tumor development could occur as a conse-
quence of cancer patients treatment, especially young 
patients, with the use of chemo- or radiotherapy that 
could exert mutagenic influence on the cells; c) en-
vironmental hazards, working conditions, immuno-
deficient state, hereditary factors (Lynch syndrome, 
Gardner syndrome). An analysis of clinical data shows 
that probability of the development of the second tu-
mor increases if the first tumor has been found in the 
patients at relatively young age [6, 7].
The difficulties in MPMT diagnosis are that mul-
tiple neoplasms do not present clinical symptoms 
typical for each tumor. In some cases clinical features 
of both tumors could be completely absent or clearly 
detected, in other cases one tumor manifests itself 
by expressed symptoms, while the signs of the second 
one are weakly expressed or “masked” by noncancer-
ous pathologies. In such cases it is difficult to assess 
the true character of the pathologic process. Complex 
diagnostics of MPMT and insufficient knowledge of this 
cancer type could lead to incorrect interpretation of the 
data obtained during clinical examination of such 
patients. The major cause of diagnostic errors is that 
sometimes after detection of the first malignant tumor 
one could underestimate the probable existence of the 
neoplasm of other genesis and don’t perform an ac-
curate examination of other organs and systems [8]. 
As far as there are none objective clinico-laboratory 
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tests and symptoms for MPMT detection, a reliable 
diagnostics could be achieved through complex ap-
proach [3, 9].
This article presents a clinical case of metastasis 
of two malignant tumors in one lymph node. The lite-
rature search has revealed no reports on metastasis 
of two tumors of different localization and histoge-
nesis in one lymph node, therefore the clinical case 
described below could be of interest to clinical on-
cologists.
Patient А., born in 1976, has been hospitalized 
in Transcarpathian Regional Clinical Oncologic Hos-
pital (Uzhhorod, Ukraine) from November 11, 2015, till 
December 02, 2015. She has appealed to oncologist 
with the complaints concerning skin neoplasm in the 
back traumatized 2 months before. Menstrual function 
within normal. Two deliveries, no abortions. According 
to the patient, there were no episodes of cancer and 
its surgical treatment in the close relatives. Allergic 
history of the patient unremarkable, she denies any 
venereal and infectious diseases.
The patient underwent complex clinical and 
laboratory exam with the following results. Com-
plete blood count: erythrocytes — 4.75•1012/l; 
leucocytes — 10.0•109/l; platelets — 489•109/l; 
hemoglobin — 141 g/l; monocytes — 0.61•109/l; 
lymphocytes — 0.62•109/l; neutrophils — 8.77•109/l. 
Biochemical blood assay: total protein — 71.0 g/l; 
urea — 7.5 mMol/l; creatinin — 114.0 mMol/l; glu-
cose — 5.0 mMol/l; alanine aminotransferase — 31.0 u; 
aspartate aminotransferase — 32.4 u; total bilirubin — 
15.7 mMol/l; conjugated bilirubin — 3.9 mMol/l. Clinical 
urinalysis: urine is light yellow transparent, pH — 6.5; 
specific weight — 1020; ketone bodies — 1+; leuco-
cytes — “−”; erythrocytes — “−”; protein — “−”.
The conducted multislice computed tomography 
revealed in lower-outer quadrant of left mammary 
gland a neoplasm with a size of 2.5 cm with patho-
logic tissue density and irregular contours, without 
microcalcinates. In left axillary region — lymph nodes 
with a diameter from 5 to 28 mm, in right axillary re-
gion — lymph nodes with a diameter up to 10 mm. 
Right lung — volume preserved, pneumatization 
satisfactory, lung picture enhanced, allowing to dif-
ferentiate small 3–4 mm lesions of median intensity, 
requiring monitoring. Left lung — at the background 
of irregular lung picture small 2–3 mm lesions, sus-
pected metastases. Liver is somewhat larger by right 
lobe. Gallbladder deformed, without concrements, 
with inhomogeneous content. Pancreas is diffusely 
dense, without cysts and pathologic lesions. Para-
aortic lymph nodes are not enlarged. As far as mul-
tislice computed tomography has been performed, the 
patient was not examined by mammography.
Clinical exam of the patient has revealed a skin 
neoplasm on left scapular line, with a size of 4.0 × 
2.5 cm and irregular dark-brown color, tuberous, with-
out signs of subcutaneous tissue infiltration and 
without ulceration. The oncologist has prepared an im-
print of this neoplasm on glass slide for cytological 
analysis. Cytological diagnosis: melanoma (conclusion 
№ 24678 from November 12, 2016). During clinical 
exam there was also revealed a tumor-like neoplasm 
in lower-outer quadrant of left mammary gland a neo-
plasm with a diameter of 2.5 cm and enlargement 
of axillary lymph nodes up to 2 cm. The neoplasm in her 
left breast the patient has explained by the trauma that 
occurred few years earlier. Clinical diagnosis: dorsal 
skin melanoma T2N1MX, clinical group II. Suspected 
breast cancer T2NXMx.
The patient provided the permission for the removal 
of dorsal skin tumor and axillary lymph nodes, but 
did not permit biopsy and removal of breast tumor. 
On November 12, 2015, the patient underwent radi-
cal excision of dorsal skin tumor along with sinistral 
axillary lymph node dissection. Pathohistological 
study of surgical material №19506–8/2015; 19509–
12/2015: from 16.11.2015. Macroscopy: on skin 
graft — exophytic neoplasm, on wide pedicle, with 
a size of 5.8 × 4 × 1.2 cm, on incision — of white-gray 
color with inclusions of black lesions. In adipose tissue 
from axillary region was studied separately, there were 
detected 5 nodules with diameter ~ from 0.4 to 4 cm, 
on incision — of white-gray color with inclusions 
of black lesions. Microscopic exam: exophytic skin 
tumor — melanoma from epithelioid cells, without 
ulceration, with moderate mitotic activity, moderate 
pigmentation, weakly expressed lymphocytic infil-
tration of stroma; III degree by Clark’s level of inva-
sion, tumor thickness by Breslow’s scale — 1.6 mm, 
satellites in a range of 2 cm from the primary tumor 
not detected. In 5 lymph nodes there were verified 
melanoma metastases from epithelioid cells with 
moderate pigmentation and moderate mitotic activity, 
in one from them — melanoma metastases together 
with з metastases of adenocarcinoma (Fig. 1, 2). His-
tochemical Perl’s reaction conducted on histological 
slides of the surgical material was found to be negative 
thus supporting the presence of melanin in the cells.
When the results of histological study of the skin 
tumor axillary lymph nodes were collected, the pa-
tient underwent core needle biopsy of tumor-like 
neoplasm in lower-outer quadrant of left mammary 
gland. Histological study from November 17, 2015, 
№ 19749–50: invasive ductal cancer G1 that is analo-
gous by its histological structure to the carcinoma 
in the lymph node. Immunohistochemical study of the 
breast tumor has revealed strongly positive expression 
of estrogen receptors (ER) and progesterone recep-
tors (PR) (Fig. 3–8).
The patient was assigned to the course of dacar-
basine (1660 mg) at monochemotherapy regime, 
and hormonal therapy with letrozole. At the next 
patient’s exam it has been found that in the area 
of postoperative cicatrix there appeared a perforation 
up to 0.5 mm. A newly performed multislice computed 
tomography has shown the following: in skin derma 
in the area of postoperative cicatrix there was de-
tected an area of pathological density up to 0.5 cm. 
In left breast two heterogeneous dense areas with 
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fig. 1. Histological preparation of lymph node with metastases 
of melanoma and adenocarcinoma: 1 — lymph node tissue 
(lymph follicles); 2 — melanoma metastases from epithelioid 
cells with moderate pigmentation in tumor cells; 3 — meta-
stases of G1 adenocarcinoma; 4 — lymph node sac (staining: 
hematoxylin-eosin, × 100)
fig. 3. Metastases of melanoma and breast cancer in lymph 
node. Immunohistochemical reaction. Expression of ER (Mono-
clonal Mouse Anti — Human Estrogen Receptor Clone 1D5, 
«Dako», chromogen DAB) in carcinoma cells. 1 — lymph node 
tissue (lymph follicle); 2 — ER expression in carcinoma cells; 
3 — immunonegative metastases of melanoma (× 100)
fig. 5. Metastases of melanoma and breast cancer in lymph 
node. Immunohistochemical reaction. Expression of PR on car-
cinoma cells (Monoclonal Mouse Anti — Human Progesterone 
Receptor Clone 1D5, «Dako», chromogen DAB). 1 — lymph fol-
licle; 2 — expression of PR; 3 — metastases of melanoma with 
moderate pigmentation (× 100)
fig. 2. Histological preparation of lymph node with metasta-
ses of melanoma and adenocarcinoma: 1 — lymph follicle; 2 — 
melanoma metastases from epithelioid cells; 3 — metastases 
of adenocarcinoma (staining: hematoxylin-eosin, × 400) 
 
fig. 4. Metastases of melanoma and breast cancer in lymph 
node. Immunohistochemical reaction. Expression of ER of differ-
ent degree on carcinoma cells (Monoclonal Mouse Anti — Human 
Estrogen Receptor Clone 1D5, «Dako», chromogen DAB). 1 — 
tissue of lymph follicle; 2 — expression of ER in adenocarcinoma 
cells; 3 — metastases of melanoma (× 100)
fig. 6. Metastases of melanoma and breast cancer in lymph 
node. Immunohistochemical reaction. Expression of PR on car-
cinoma cells (Monoclonal Mouse Anti — Human Progesterone 
Receptor Clone 1D5, «Dako», chromogen DAB). 1 — lymph 
follicle; 2 — expression of PR in adenocarcinoma cells; 3 — 
metastases of melanoma (× 400)
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the diameters of 21 and 24 mm in upper and lower 
lateral quadrants were detected. The signs of bilat-
eral lung carcinomatosis, pleural cavities free. In the 
abdomen no liquid was detected. Liver moderately 
enlarged, of regular structure. Gallbladder without 
concrements. Pancreas, spleen, adrenals without 
pathologic changes. Uterus with a size of 55 × 40 mm, 
adnexa not enlarged. In parametrium small amount 
of liquid. In vertebral bodies no destructive changes 
were detected. Brain: no area of pathologic density 
were detected, midline structures are symmetric, sub-
arachnoid space within normal.
On December 22, 2015, the patient was treated 
by repeated surgery: removal of skin graft with sub-
cutaneous fat and dermal neoplasm and extirpation 
of lymph node at the level of left axillary area. Histo-
logical conclusion from 29.12.2015 № 15CSD34744: 
in lymph node of skin graft in separately examined 
lymph node from left axillary area — melanoma 
metastases from epithelioid cells with moderate pig-
mentation and moderate mitotic activity. Then core 
needle biopsy of tumor-like neoplasm in upper-lateral 
quadrant of left breast was conducted. Histological 
conclusion from 29.12.2015 № 15CSD34052: invasive 
duct carcinoma G1 of mammary gland, by the results 
of immunohistochemical study — of luminal B subtype: 
ER “+++”; PR “+++”; HER2/neu “—”; also, 20% of tu-
mor cells were positive for expression of proliferation 
marker Ki-67.
So, based on abovementioned results, the final 
clinical diagnosis was established: multiple pri-
mary synchronous tumors — dorsal skin melanoma 
pT2bpN2M1 pulm; invasive multicentric ductal cancer 
G1 pT2(2)pN1pM0, Lum B in left mammary gland; pro-
longation of tumor process, metastasis of melanoma 
in skin and lungs. In 2016 the patient has been treated 
with 6 courses of dacarbasine (1660 mg) at mono-
therapy regime, and hormonal therapy with letrozole 
(2.5 mg daily) for 6 months, after which there were 
registered stabilization of melanoma and regression 
of breast tumors by 25%.
In conclusion, the described clinical case of mul-
tiple primary tumors demonstrates on the possibility 
of metastasis of two tumors of different genesis and 
different primary localization — melanoma and breast 
cancer — in one lymph node, that is evidenced by the 
results of complex clinical and X-ray exam of the 
patient as well as the data of morphologic and im-
munohistochemical study of the surgical material — 
dorsal skin and axillary lymph nodes. By the disease 
anamnesis, we could not determine which one of the 
tumors was the primary one as well as the causes 
of their development. Such problems often arise in the 
cases of multiple primary cancers, so these patholo-
gies require further studies.
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fig. 7. Invasive ductal breast cancer. Immunohistochemical 
reaction. Expression of ER on carcinoma cells (Monoclonal 
Mouse Anti — Human Estrogen Receptor Clone 1D5, «Dako», 
chromogen DAB). 1 — expression of ER; 2 — connective tissue; 
3 — adipose tissue (× 100)
fig. 8. Invasive ductal breast cancer. Immunohistochemical 
reaction. Expression of ER on carcinoma cells (Monoclonal 
Mouse Anti — Human Estrogen Receptor Clone 1D5, «Dako», 
chromogen DAB). 1 — expression of ER; 2 — connective tis-
sue (× 400)
